Published in Chest on June 01, 1998
Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev (2001) 3.58
Moraxella catarrhalis: from emerging to established pathogen. Clin Microbiol Rev (2002) 2.43
Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax (2000) 1.65
Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis (2012) 1.55
Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2008) 1.24
Elastase- and LPS-exposed mice display altered responses to rhinovirus infection. Am J Physiol Lung Cell Mol Physiol (2009) 1.18
Chronic obstructive pulmonary disease . 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax (2003) 1.14
Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax (2006) 1.04
Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis (2014) 1.02
Lung microbiology and exacerbations in COPD. Int J Chron Obstruct Pulmon Dis (2012) 1.01
Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 0.99
Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm Med (2014) 0.97
Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis (2007) 0.92
Prevention of lung injury by Muc1 mucin in a mouse model of repetitive Pseudomonas aeruginosa infection. Inflamm Res (2012) 0.89
Relationship between the GOLD combined COPD assessment staging system and bacterial isolation. Int J Chron Obstruct Pulmon Dis (2014) 0.87
Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. Antimicrob Agents Chemother (2011) 0.85
Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis. Int J Chron Obstruct Pulmon Dis (2007) 0.83
Clinical features, etiology and outcomes of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. PLoS One (2014) 0.83
Cigarette smoke decreases airway epithelial FABP5 expression and promotes Pseudomonas aeruginosa infection. PLoS One (2013) 0.82
Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2013) 0.81
Assessment of some inflammatory biomarkers as predictors of outcome of acute respiratory failure on top of chronic obstructive pulmonary disease and evaluation of the role of bacteria. ISRN Microbiol (2012) 0.77
Identification of outer membrane Porin D as a vitronectin-binding factor in cystic fibrosis clinical isolates of Pseudomonas aeruginosa. J Cyst Fibros (2015) 0.77
Bacterial flora in the sputum and comorbidity in patients with acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.77
Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation. Int J Chron Obstruct Pulmon Dis (2016) 0.76
Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care. Int J Chron Obstruct Pulmon Dis (2009) 0.76
Quantitative analysis of pathogens in the lower respiratory tract of patients with chronic obstructive pulmonary disease. BMC Pulm Med (2015) 0.75
Infective exacerbations of COPD. Chest (1999) 0.75
Effectiveness of treatment with nebulized colistin in patients with COPD. Int J Chron Obstruct Pulmon Dis (2017) 0.75
[Community-acquired and nosocomial pneumonia]. Internist (Berl) (2003) 0.75
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med (2001) 9.08
Differentiation of phylogenetically related slowly growing mycobacteria based on 16S-23S rRNA gene internal transcribed spacer sequences. J Clin Microbiol (1998) 4.82
Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother (1985) 4.07
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother (1994) 3.73
Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis (1993) 3.68
Novel diagnostic algorithm for identification of mycobacteria using genus-specific amplification of the 16S-23S rRNA gene spacer and restriction endonucleases. J Clin Microbiol (2000) 3.64
Guidelines for the management of adult lower respiratory tract infections. Eur Respir J (2005) 3.51
Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect (2011) 2.99
Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest (1997) 2.78
[Azlocillin and mezlocillin: two new semisynthetic acylureido-penicillins (author's transl)]. Infection (1977) 2.54
Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest (1997) 2.32
Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrob Agents Chemother (1979) 2.23
Use of investigations in lower respiratory tract infection in the community: a European survey. Eur Respir J (1996) 2.22
Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis (2007) 2.21
Clinical evaluation of a Mycobacterium tuberculosis PCR assay. J Clin Microbiol (1995) 2.19
Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J (1996) 2.18
Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines. Eur Respir J (2011) 2.13
A "closed" medical intensive care unit (MICU) improves resource utilization when compared with an "open" MICU. Am J Respir Crit Care Med (1998) 2.03
Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol (1986) 2.00
Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med (1998) 1.99
Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J (2006) 1.91
Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Eur Respir J (1996) 1.87
Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol (1985) 1.86
Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother (2000) 1.80
Clostridium difficile infection as a cause of severe sepsis. Intensive Care Med (1996) 1.75
Blood cultures have limited value in predicting severity of illness and as a diagnostic tool in ventilator-associated pneumonia. Chest (1999) 1.67
AIDS in a bodybuilder using anabolic steroids. N Engl J Med (1984) 1.66
Utility of fiberoptic bronchoscopy in nonresolving pneumonia. Chest (1990) 1.64
Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J (2006) 1.55
Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir Res (2006) 1.54
Drug-resistant pulmonary tuberculosis in Berlin, Germany, 1987-1993. Eur Respir J (1995) 1.52
Mycobacterium heckeshornense sp. nov., A new pathogenic slowly growing Mycobacterium sp. Causing cavitary lung disease in an immunocompetent patient. J Clin Microbiol (2000) 1.52
Increased number of alveolar macrophages expressing adhesion molecules of the leukocyte adhesion molecule family in smoking subjects. Association with cell-binding ability and superoxide anion production. Am Rev Respir Dis (1992) 1.49
Comparison of bacterial adherence to ciliated and squamous epithelial cells obtained from the human respiratory tract. Am Rev Respir Dis (1983) 1.47
Comparative pharmacokinetics of cefoperazone and cefotaxime. Clin Ther (1980) 1.46
[Pneumococcal vaccination: conjugated vaccine induces herd immunity and reduces antibiotic resistance]. Dtsch Med Wochenschr (2008) 1.45
Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J (1999) 1.42
The role of bacteria in exacerbations of COPD. A constructive view. Chest (2000) 1.42
Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest (2000) 1.41
Azithromycin--review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother (1996) 1.40
Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J (2006) 1.40
Antibiotic prescribing for discoloured sputum in acute cough/lower respiratory tract infection. Eur Respir J (2011) 1.39
Antiviral treatment and prophylaxis of influenza in primary care: German recommendations. J Clin Virol (2004) 1.39
Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother (1983) 1.39
Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med (1997) 1.34
Mixed community-acquired pneumonia in hospitalised patients. Eur Respir J (2006) 1.29
Comparative pharmacokinetics of apalcillin and piperacillin. Antimicrob Agents Chemother (1984) 1.28
Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states : 1993, 1995, and 1997. Chest (2001) 1.28
Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care. Eur Respir J (2006) 1.28
Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis (2000) 1.27
[Comparative clinical pharmacology of gentamicin, sisomicin, and tobramycin]. Antimicrob Agents Chemother (1975) 1.26
Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J (2003) 1.24
Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother (1999) 1.24
Determination of apalcillin and its metabolites in human body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother (1982) 1.19
Tsukamurella tyrosinosolvens sp. nov. Int J Syst Bacteriol (1997) 1.19
Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother (1996) 1.19
Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. Clin Infect Dis (1992) 1.17
Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis (1996) 1.12
Effectiveness of the macrolide clarithromycin in the treatment of Mycobacterium avium complex infection in HIV-infected patients. Infection (1992) 1.11
Guidelines for the management of adult lower respiratory tract infections--summary. Clin Microbiol Infect (2011) 1.11
Respiratory infection complicating long-term tracheostomy. The implication of persistent gram-negative tracheobronchial colonization. Chest (1984) 1.10
Determination of cefmenoxime in human body fluids by high-performance liquid chromatography. Eur J Clin Microbiol (1983) 1.08
[Recommendations for environmental contact tracing in tuberculosis. German Central Committee against Tuberculosis]. Gesundheitswesen (2007) 1.08
Multiple dose pharmacokinetics and therapeutic results with ceftazidime. J Antimicrob Chemother (1983) 1.07
Non-cardiogenic pulmonary edema after pericardial drainage for cardiac tamponade. Chest (1988) 1.05
Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med (1997) 1.05
Amplification of Mycobacterium tuberculosis from peripheral blood. J Clin Microbiol (1995) 1.03
Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother (1983) 1.03
Toxicity of quinolones. Drugs (1999) 1.03
Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother (1992) 1.02
Is "crop rotation" of antibiotics the solution to a "resistant" problem in the ICU? Am J Respir Crit Care Med (1997) 1.02
[Recommendations for background studies in tuberculosis]. Pneumologie (2007) 1.01
Pneumonia complicating pregnancy. Clin Chest Med (1992) 1.01
Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. Clin Infect Dis (1996) 1.01
Improved method for the cyanogen bromide activation of agarose beads. J Chromatogr (1979) 1.00
Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother (1989) 1.00
Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother (1992) 1.00
Biliary excretion and pharmacokinetics of cefoperazone in humans. J Antimicrob Chemother (1983) 0.99
Elimination of ampicillin and gentamicin by hemofiltration. Klin Wochenschr (1979) 0.99
Molecular diagnosis of tuberculosis: current clinical validity and future perspectives. Eur Respir J (1997) 0.98
Lymphocyte subsets in peripheral blood and smoking habits. Lung (1997) 0.98
Cefotaxime in bronchopulmonary infections--a clinical and pharmacological study. J Antimicrob Chemother (1980) 0.98
Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother (1988) 0.97
A prediction model for bacterial etiology in acute exacerbations of COPD. Infection (2007) 0.97
Rapid drug susceptibility testing of Mycobacterium tuberculosis using conventional solid media. Eur Respir J (1995) 0.97
Phenotypically activated gammadelta T lymphocytes in the peripheral blood of patients with tuberculosis. J Infect Dis (1999) 0.97
Initial antimicrobial treatment of hospital acquired pneumonia in adults: A conference report. Can J Infect Dis (1993) 0.97
Surfactant protein A modulates release of reactive oxygen species from alveolar macrophages. Am J Physiol (1994) 0.97
Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids. J Clin Chem Clin Biochem (1986) 0.97
Cells and cytokines in chronic bronchial infection. Ann N Y Acad Sci (1994) 0.96